323 related articles for article (PubMed ID: 35152220)
1. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
2. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
3. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
4. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
[TBL] [Abstract][Full Text] [Related]
5. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
6. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
[TBL] [Abstract][Full Text] [Related]
7. [VEGFRs in neoplastic angiogenesis and prospects for therapy of brain tumors].
Korchagina AA; Shein SA; Gurina OI; Chekhonin VP
Vestn Ross Akad Med Nauk; 2013; (11):104-14. PubMed ID: 24640739
[TBL] [Abstract][Full Text] [Related]
8. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
9. Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.
Yang J; Wang Q; Qiao C; Lin Z; Li X; Huang Y; Zhou T; Li Y; Shen B; Lv M; Feng J
Cell Mol Immunol; 2014 May; 11(3):285-93. PubMed ID: 24608894
[TBL] [Abstract][Full Text] [Related]
10. VEGF signaling in cancer treatment.
Sia D; Alsinet C; Newell P; Villanueva A
Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells.
Jung HJ; Kim Y; Chang J; Kang SW; Kim JH; Kwon HJ
J Mol Med (Berl); 2013 Sep; 91(9):1117-28. PubMed ID: 23708980
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
14. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
Cho HD; Lee KW; Won YS; Kim JH; Seo KI
J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
[TBL] [Abstract][Full Text] [Related]
15. Targeting CXCR4-dependent immunosuppressive Ly6C
Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.
Grothey A; Galanis E
Nat Rev Clin Oncol; 2009 Sep; 6(9):507-18. PubMed ID: 19636328
[TBL] [Abstract][Full Text] [Related]
18. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
19. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
20. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
